Pulmozyme

Dornase alfa

Dornase alfa

Pharmaceutical drug

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]

Quick Facts Clinical data, Trade names ...

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]

Society and culture

Dornase alfa is an orphan drug.[4]

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5][6]

References

  1. [1]
    Product guildlink.com.au
  2. [2]
    "Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
  3. [3]
    "Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
  4. [4]
    Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
  5. [5]
    Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511. PMID 17436388.
  6. [6]
    Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.
Share this article:

This article uses material from the Wikipedia article Pulmozyme, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.